.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,741,908

« Back to Dashboard

Details for Patent: 8,741,908

Title:Inhibitors of bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure of Formula (B) ##STR00001## Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:Dec 29, 2011
Application Number:13/340,556
Claims:1. A compound of Formula (B) having the structure: ##STR00057## wherein: Y is alkylene or substituted alkylene, or a 4-, 5-, 6-membered cycloalkylene ring; each R.sub.a is independently H, halogen, --CF.sub.3, --CN, --NO.sub.2, OH, NH.sub.2, -L.sub.a-(substituted or unsubstituted alkyl), -L.sub.a-(substituted or unsubstituted alkenyl), or -L.sub.a-(substituted or unsubstituted heteroaryl), wherein L.sub.a is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, NH, C(O), CH.sub.2, --NHC(O)O, --NHC(O), or --C(O)NH; G is ##STR00058## R.sub.2 is selected from H, lower alkyl, and substituted lower alkyl; R.sub.6, R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; R.sub.12 is H or lower alkyl; or Y and R.sub.12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or a pharmaceutically acceptable solvate, pharmaceutically acceptable hydrate, or pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein G is ##STR00059##

3. The compound of claim 2, wherein R.sub.6, R.sub.7, and R.sub.8 are H.

4. The compound of claim 2, wherein R.sub.7 and R.sub.8 are H; and R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

5. The compound of claim 4, wherein R.sub.6 is substituted lower alkyl.

6. The compound of claim 5, wherein lower alkyl is substituted with a disubstituted amino group.

7. The compound of claim 2, wherein R.sub.6 and R.sub.8 are H; and R.sub.7 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

8. The compound of claim 7, wherein R.sub.7 is substituted lower alkyl.

9. The compound of claim 8, wherein lower alkyl is substituted with a disubstituted amino group.

10. The compound of claim 1, wherein G is ##STR00060##

11. The compound of claim 10, wherein R.sub.6 is H.

12. The compound of claim 10, wherein R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

13. The compound of claim 12, wherein R.sub.6 is substituted lower alkyl.

14. The compound of claim 13, wherein lower alkyl is substituted with a disubstituted amino group.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition of claim 15 that is formulated for a route of administration selected from oral administration, parenteral administration, buccal administration, nasal administration, topical administration, or rectal administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc